 |
|
|
|
 |
|
|
| Article 1 to 5 out of 5 concerning Max-Planck-Innovation GmbH
|
-
Alnylam and Isis Announce Allowance of First U.S. Patent Covering Human microRNAs
(03/05/2007)
Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc. announced that the United States Patent and Trademark Office (USPTO) has allowed claims in a patent application that covers microRNAs (miRNAs) and therapeutic molecules that target these ...
-
Stratagene Acquires Rights to microRNA Sequences
(02/07/2007)
Co-Exclusive License Provides Access to More Than 150 microRNA Sequences for the Development, Manufacture and Sale of Molecular Diagnostic Kits
Stratagene Corporation announced that it has obtained the last of the four co-exclusive licenses to more than 150 microRNA sequences available from Max Planck Innovation, the technology transfer agency of the Max Planck Society. Under the terms of ...
-
Alnylam Announces Allowance of U.S. Patent Broadly Covering RNAi Therapeutics
(01/19/2006)
Patent Rights for Tuschl II are Held Exclusively by Alnylam for Development and Commercialization of RNAi Therapeutics
Alnylam Pharmaceuticals, Inc. announced that the United States Patent and Trademark Office (USPTO) has allowed claims in a patent application that broadly covers methods for preparing small interfering RNAs (siRNAs), the molecules that mediate RNAi. ...
-
SuppreMol launched as a new company
(11/30/2005)
Z-Cube, the corporate venture capital arm of the Zambon Group took another important step forwards in fostering pharmaceutical innovation, signing a contract to provide finance and expert support to SuppreMol GmbH. This marked the project's official ...
-
OncoMethylome Sciences Licenses Technology from the Max-Planck-Institute for Detecting Novel Methylated Genes
(05/19/2005)
OncoMethylome Sciences and the Max Planck Society announced that OncoMethylome Sciences has been granted an exclusive license to intellectual property developed by the Max-Planck-Institute (MPI) of Biochemistry involving the silencing of several ...
|
|
|
|
|
Top
